| scholarly article | Q13442814 |
| P50 | author | Ralph A. DeFronzo | Q58689309 |
| P2093 | author name string | J Adams | |
| C Triplitt | |||
| E Cersosimo | |||
| M A Abdul-Ghani | |||
| C Puckett | |||
| D Maggs | |||
| P2860 | cites work | Pioglitazone for diabetes prevention in impaired glucose tolerance. | Q51161029 |
| Thiazolidinediones improve beta-cell function in type 2 diabetic patients. | Q51485541 | ||
| Effects of pioglitazone on beta-cell function in metabolic syndrome patients with impaired glucose tolerance. | Q51496669 | ||
| Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. | Q51586347 | ||
| Effect of metformin treatment on insulin action in diabetic rats: in vivo and in vitro correlations. | Q51616426 | ||
| Relation of glycemic control to diabetic microvascular complications in diabetes mellitus | Q70880944 | ||
| United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years | Q72448175 | ||
| Glycemic control and prevention of retinopathy in Japanese NIDDM patients. A 10-year follow-up study | Q73209712 | ||
| Effects of pioglitazone and metformin on beta-cell function in nondiabetic subjects at high risk for type 2 diabetes | Q80250944 | ||
| Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial | Q84342991 | ||
| Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Q22241288 | ||
| One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial | Q24656644 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 | ||
| Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes | Q29547541 | ||
| Effects of intensive glucose lowering in type 2 diabetes | Q29547736 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| Secondary failure of metformin monotherapy in clinical practice | Q33683607 | ||
| Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach | Q34294997 | ||
| Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes | Q34424907 | ||
| The biology of incretin hormones | Q34499706 | ||
| Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial | Q34572519 | ||
| Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 | ||
| Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes | Q35179964 | ||
| Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial | Q36249636 | ||
| Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society | Q36782795 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? | Q37364945 | ||
| Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study | Q38044043 | ||
| Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks | Q41831179 | ||
| Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial | Q41832904 | ||
| Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study | Q42691702 | ||
| Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study | Q43959543 | ||
| The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose | Q44493423 | ||
| Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. | Q44924385 | ||
| P433 | issue | 3 | |
| P921 | main subject | metformin | Q19484 |
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 268-275 | |
| P577 | publication date | 2015-01-07 | |
| P1433 | published in | Diabetes, Obesity and Metabolism | Q5270109 |
| P1476 | title | Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial | |
| P478 | volume | 17 |
| Q41623756 | A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus |
| Q50333496 | A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products. |
| Q40348845 | Allele frequency and genotype distribution of a common variant in the 3´-untranslated region of the SLC22A3 gene in patients with type 2 diabetes: Association with response to metformin |
| Q40251170 | Association between the synonymous variant organic cation transporter 3 (OCT3)-1233G>A and the glycemic response following metformin therapy in patients with type 2 diabetes |
| Q90696670 | Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin-metformin combination in newly diagnosed Type 2 diabetes |
| Q47849041 | Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? |
| Q39578134 | Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes |
| Q51185982 | Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. |
| Q39255963 | Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor |
| Q49193708 | Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin |
| Q90402115 | Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases |
| Q38762377 | Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. |
| Q58697117 | Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis |
| Q58700185 | Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial |
| Q39368551 | Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised c |
| Q93004687 | Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme |
| Q89949315 | Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study |
| Q47755876 | Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. |
| Q47137951 | Jia-Wei-Jiao-Tai-Wan ameliorates type 2 diabetes by improving β cell function and reducing insulin resistance in diabetic rats |
| Q55020927 | Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study. |
| Q57026285 | Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) |
| Q56979722 | Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) |
| Q38650414 | Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study. |
| Q96135149 | Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus |
| Q92835456 | Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes |
| Q91492192 | Real-world diabetes prevention: from theory to practice |
| Q42373168 | Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date |
| Q91492188 | Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES) |
| Q54916848 | Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration. |
| Q37652799 | The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema. |
| Q92771766 | Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study |
| Q64069458 | Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia |
| Q64997065 | Therapeutic strategies for type 2 diabetes mellitus patients with very high HbA1c: is insulin the only option? |
| Q100748199 | Time to Reach Target Glycosylated Hemoglobin Is Associated with Long-Term Durable Glycemic Control and Risk of Diabetic Complications in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A 6-Year Observational Study |
| Q92391721 | Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes |
| Q58447602 | Type 2 diabetes mellitus |
| Q90201467 | VERIFY the role of initial combination therapy in patients with type 2 diabetes |
Search more.